Skip to Content
Merck
CN
  • Accelerated protocol for the differentiation of podocytes from human pluripotent stem cells.

Accelerated protocol for the differentiation of podocytes from human pluripotent stem cells.

STAR protocols (2021-11-09)
Julie Bejoy, Eddie Spencer Qian, Lauren Elizabeth Woodard
ABSTRACT

Several kidney diseases including congenital nephrotic syndrome, Alport syndrome, and diabetic nephropathy are linked to podocyte dysfunction. Human podocytopathies may be modeled in either primary or immortalized podocyte cell lines. Human induced pluripotent stem cell (hiPSC)-derived podocytes are a source of human podocytes, but the existing protocols have variable efficiency and expensive media components. We developed an accelerated, feeder-free protocol for deriving functional, mature podocytes from hiPSCs in only 12 days, saving time and money compared with other approaches.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium azide, ReagentPlus®, ≥99.5%
Sigma-Aldrich
TWEEN® 20, Molecular Biology, viscous liquid
Sigma-Aldrich
Dimethyl sulfoxide, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%